Moberg Pharma AB (publ) (MOB.ST)
SEK 7.08
(-1.8%)
SEK 7.08
(-1.8%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -26.95 Million SEK | -59.91% |
| 2022 | -16.85 Million SEK | 2.31% |
| 2021 | -17.14 Million SEK | 9.88% |
| 2020 | 12.58 Million SEK | 0.0% |
| 2018 | -3.24 Million SEK | 28.19% |
| 2017 | 89.44 Million SEK | 97.32% |
| 2016 | 83.53 Million SEK | -19.35% |
| 2015 | 46.43 Million SEK | 78.1% |
| 2014 | 25.96 Million SEK | 433.44% |
| 2013 | -7.78 Million SEK | -149.66% |
| 2012 | 15.69 Million SEK | 366.12% |
| 2011 | -5.89 Million SEK | 80.23% |
| 2010 | -29.8 Million SEK | -23.89% |
| 2009 | -24.06 Million SEK | 31.65% |
| 2008 | -35.2 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -5.43 Million SEK | 23.73% |
| 2024 Q1 | -7.12 Million SEK | 0.75% |
| 2023 Q3 | -6.27 Million SEK | -50.49% |
| 2023 Q1 | -5.43 Million SEK | -71.57% |
| 2023 FY | - SEK | -56.7% |
| 2023 Q2 | -4.17 Million SEK | 23.28% |
| 2023 Q4 | -8.23 Million SEK | -31.15% |
| 2022 Q2 | -4.29 Million SEK | 10.05% |
| 2022 Q1 | -4.77 Million SEK | -9.67% |
| 2022 FY | - SEK | 2.31% |
| 2022 Q3 | -4.61 Million SEK | -7.5% |
| 2022 Q4 | -3.16 Million SEK | 31.38% |
| 2021 FY | - SEK | 9.88% |
| 2021 Q4 | -4.35 Million SEK | -8.68% |
| 2021 Q1 | -5.42 Million SEK | -1.42% |
| 2021 Q2 | -3.47 Million SEK | 35.92% |
| 2021 Q3 | -4 Million SEK | -15.34% |
| 2020 FY | - SEK | 0.0% |
| 2020 Q1 | -3.58 Million SEK | 22.24% |
| 2020 Q4 | -5.34 Million SEK | -17.24% |
| 2020 Q2 | -5.66 Million SEK | -57.92% |
| 2020 Q3 | -4.55 Million SEK | 19.45% |
| 2019 Q4 | -4.6 Million SEK | -110.87% |
| 2019 Q1 | 14.86 Million SEK | -56.49% |
| 2019 Q3 | 42.39 Million SEK | 596.63% |
| 2019 Q2 | -8.53 Million SEK | -157.43% |
| 2018 Q2 | 20.31 Million SEK | -7.35% |
| 2018 FY | - SEK | 28.19% |
| 2018 Q4 | 34.16 Million SEK | 50.63% |
| 2018 Q3 | 22.68 Million SEK | 11.64% |
| 2018 Q1 | 21.92 Million SEK | -40.98% |
| 2017 Q3 | 35.3 Million SEK | 260.47% |
| 2017 FY | - SEK | 97.32% |
| 2017 Q1 | 16.66 Million SEK | 508.28% |
| 2017 Q4 | 37.15 Million SEK | 5.23% |
| 2017 Q2 | 9.79 Million SEK | -41.23% |
| 2016 FY | - SEK | -19.35% |
| 2016 Q1 | 3.49 Million SEK | -9.22% |
| 2016 Q2 | 42.28 Million SEK | 1109.06% |
| 2016 Q3 | 34.72 Million SEK | -17.88% |
| 2016 Q4 | -4.08 Million SEK | -111.76% |
| 2015 FY | - SEK | 78.1% |
| 2015 Q1 | 17.38 Million SEK | 396.52% |
| 2015 Q3 | 13.84 Million SEK | 24.18% |
| 2015 Q2 | 11.15 Million SEK | -35.87% |
| 2015 Q4 | 3.85 Million SEK | -72.18% |
| 2014 Q4 | 3.5 Million SEK | -59.02% |
| 2014 Q2 | 7.8 Million SEK | 1.83% |
| 2014 Q1 | 7.66 Million SEK | 330.3% |
| 2014 FY | - SEK | 433.44% |
| 2014 Q3 | 8.54 Million SEK | 9.45% |
| 2013 FY | - SEK | -149.66% |
| 2013 Q4 | 1.78 Million SEK | 168.7% |
| 2013 Q3 | -2.59 Million SEK | 46.75% |
| 2013 Q2 | -4.87 Million SEK | -131.84% |
| 2013 Q1 | -2.1 Million SEK | -1554.33% |
| 2012 Q2 | 1.91 Million SEK | -77.5% |
| 2012 Q1 | 8.49 Million SEK | 90.1% |
| 2012 FY | - SEK | 366.12% |
| 2012 Q4 | -127 Thousand SEK | -102.81% |
| 2012 Q3 | 4.52 Million SEK | 136.75% |
| 2011 Q2 | -9.49 Million SEK | -43.85% |
| 2011 Q4 | 4.46 Million SEK | -22.06% |
| 2011 Q3 | 5.73 Million SEK | 160.37% |
| 2011 Q1 | -6.59 Million SEK | 25.57% |
| 2011 FY | - SEK | 80.23% |
| 2010 Q1 | -4.64 Million SEK | 0.0% |
| 2010 FY | - SEK | -23.89% |
| 2010 Q3 | -8.33 Million SEK | -4.67% |
| 2010 Q4 | -8.86 Million SEK | -6.32% |
| 2010 Q2 | -7.96 Million SEK | -71.67% |
| 2009 FY | - SEK | 31.65% |
| 2008 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AcuCort AB | -13.69 Million SEK | -96.913% |
| AlzeCure Pharma AB (publ) | -37.86 Million SEK | 28.807% |
| BioGaia AB (publ) | 466.19 Million SEK | 105.783% |
| Enzymatica AB (publ) | -41.12 Million SEK | 34.441% |
| Enorama Pharma AB (publ) | -43.05 Million SEK | 37.381% |
| Gabather AB (publ) | 37 Thousand SEK | 72963.065% |
| Klaria Pharma Holding AB (publ.) | -14.77 Million SEK | -82.528% |
| Nanexa AB (publ) | -70.79 Million SEK | 61.917% |
| Newbury Pharmaceuticals AB (publ) | -12.34 Million SEK | -118.471% |
| ODI Pharma AB | 1.36 Million SEK | 2071.63% |
| Orexo AB (publ) | -22 Million SEK | -22.542% |
| Probi AB (publ) | 115.61 Million SEK | 123.319% |
| Swedencare AB (publ) | 484 Million SEK | 105.57% |
| Swedish Orphan Biovitrum AB (publ) | 7.23 Billion SEK | 100.373% |
| Toleranzia AB | -7.39 Million SEK | -264.414% |
| Vivesto AB | -89.75 Million SEK | 69.964% |